Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized trial of azithromycin pretreatment to reduce anti-TNF immunogenicity in Crohn's disease
MOH_2023-04-04_012048Phase 2Not yet recruiting
- Sponsor
- חגי בר-יוסף
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azithromycin in Crohn's disease (2 arms), sponsored by חגי בר-יוסף. Primary endpoint: Development of anti-drug antibodies at 1 year. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
azithromycin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2023-04-04_012048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-04_012048.